Dr. Lynn Daboul is a current neuromuscular fellow at Mass General Brigham. She earned her medical degree as well as a master’s degree in clinical research from the Cleveland Clinic Lerner College of Medicine. She went on to complete her neurology residency training at Mass General Brigham in June 2025.

Dr. Daboul has interests in biomarkers, autoimmune neurology, and multicenter clinical trials. As part of her work at the NIH as a Medical Research Scholars Program Fellow, she collaborated with investigators at multiple institutions in exploring the central vein sign (CVS) as a biomarker for diagnosing MS. The collaborative work she did on the CVS was ultimately cited in the 2024 Revision of the McDonald Criteria, which now incorporates the Select 6 method of determining CVS positivity in establishing an MS diagnosis. She is currently interested in pursuing research in biomarker validation and drug development, particularly for inflammatory neuromuscular disorders.